CHDI Foundation extends collaboration with IRBM to accelerate development of Huntington’s disease therapeutics
Pomezia, Italy, November 19th 2018 – IRBM, a global contract research organization (CRO), has strengthened its position in neurodegenerative disease research following an extension of its long-standing collaboration with CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease (HD).
Pomezia, Italy, June 19, 2018 – IRBM will be providing services using human induced pluripotent stem cells (hiPSCs) based on the iPS cell-related patents that have been sublicensed to iPS Academia Japan by Kyoto University.
WASHINGTON, D.C., August 20, 2017 – At a ceremony prior to the American Chemical Society fall meeting, the ACS inducted Dr. Vincenzo Summa and Dr. Steven Harper, respectively the Vice President of Drug Discovery and the Head of Medicinal Chemistry at IRBM Science Park S.p.A., into its scientific Hall of Fame as Heroes of Chemistry, 2017. The program recognizes scientists whose innovative work in chemistry and chemical engineering led to commercial products that benefit the world.
MILAN, June 20, 2017 – IRBM announced today that a scientific consortium led by its subsidiary Promidis received a 5.6 million euro grant from the Italian region of Lombardy to discover and develop innovative cures for chronic hepatitis B, a disease which still affects a significant portion of the world population, despite the availability of a vaccine. Chronic hepatitis B is a significant burden on national health systems, and can lead to severe complications, especially in children.
ROME, May 18, 2017 – IRBM Science Park S.p.A., alongside other public and private institutions, has supported the activities of the HDdennomore international network, a group of organizations focused on raising awareness and support for Huntington’s disease sufferers worldwide.
ROME, September 15, 2016 – IRBM Science Park S.p.A. is among eight research institutions, both private and public, which have been awarded the 12.6 million euro grant, BRAVEinMS, issued by the Progressive MS Alliance.
VITERBO (VT), June 30, 2016 – IRBM’s CNCCS consortium joined the Università della Tuscia, the Italian National Research Council (CNR), and the Italian Department of Instruction, University and Research (MIUR) in announcing the joint PRONAT project, aimed at identifying bioactive agents of animal or plant origin.